Browsing by Author "Kravchun, Nonna"

Now showing 1 - 10 of 10

Adipokines vaspin and omentin as risk markers of disorders of carbo- hydrate metabolism development in overweight and obese patients
(2020-09) Karachentsev, Iurii; Kravchun, Nonna; Misiura, Katerina; Dunaieva, Inna; Alhamid, Mohamad Hussain
Important role of fractalkine and omentin in pathogenesis of diabetes mel- litus in obesity was proved. The correlation was established between the adipose tissue accumulation, changes in its endocrine function, development of inflammatory processes in the body, abdominal obesity, insulin resistance and type 2 diabetes mellitus onset.
Albuminuria as an Independent Factor of Cardiovascular Complications in Patients with Comorbid Pathology
(2022-10) Біловол, Олександр Миколайович; Кравчун, Нонна Олександрівна;; Земляниціна, Ольга В’ячеславівна; Дунаєва, Інна Павлівна; Чернявська, Ірина Вікторівна; Bilovol, Olexandr; Kravchun, Nonna; Zemlianitsyna, Olga; Dunaieva, Inna; Cherniavskaya, Iryna
The necessity of determining and assessing the dynamics of albuminuria and glomerular filtration rate in patients with type 1 and type 2 DM (as an early marker of endothelial dysfunction and a predictor of cardiovascular complications) was substantiated amid pathogenetic therapy with glycosaminoglycan sulodexide. There is a clinically significant decrease in the levels of both total protein and albumin in the urine, which along with an increase in glomerular filtration rate indicates an improvement in renal microcirculation. It is worth pointing out that the increase in glomerular filtration rate is mostly evident among type 2 DM patients with comorbid non-alcoholic fatty liver disease.
The course of chronic heart failure in persons with postinfarction cardiosclerosis with arterial hypertension and type 2 diabetes mellitus and obesity according to a number of MET
(Wolters Kluwer Health, Inc., 2023-07) Kravchun, Nonna; Kravchun, Pavlo; Dunaieva, Inna
A retrospective analysis of a comprehensive examination of 67 patients with postinfarction cardiosclerosis with concomitant type 2 diabetes and obesity. All patients were divided into 3 groups depending on the functional class (FC) of CHF: 1 group (n = 22) - patients with CHF II FC; Group 2 (n = 23) - patients with CHF III FC; Group 3 (n = 22) - patients with CHF IV FC. All patients were examined clinically, they underwent instrumental, biochemical and hormonal examinations. Due to the progression of chronic heart failure in patients with postinfarction cardiosclerosis and AH concomitant type 2 diabetes and obesity, an increase in all fractions of lipoproteins at stage III functional class was diagnosed, and then their decrease, which may indicate a deterioration in this category of patients, due to the progression of metabolic shifts, stagnation, dysfunction of the main parenchymal organs. Increased circulatory levels of fractalkin and decreased clusterin content in patients with postinfarction cardiosclerosis with concomitant type 2 diabetes mellitus and obesity is accompanied by an increase in the functional class of chronic heart failure.
Experience of Using Sodium-dependent Glucose Cotransporter Type 2 Inhibitors in Comorbid Patients in Real Clinical Practice
(Acta Scientific, 2023-02-08) Kravchun, Nonna; Dunaieva, Inna; Kravchun, Pavlo
Inhibitors of sodium-dependent glucose cotransporter type 2 (SGLT2i) are drugs that protect against cardiovascular diseases and mortality in patients with diabetes mellitus (DM) type 2 of various age groups with the presence of comorbid pathology and numerous complications. The huge number of achieved results may vary in different cases, but already existing data prove the importance and necessity of prescribing such innovative drugs as SGLT2i. So far, the effectiveness and necessity of using SGLT2i has been proven not only in patients with type 2 diabetes, but also in patients with heart failure and chronic kidney disease without diabetes. The Aim of the Study: An analysis of the long-term results of the influence of combined therapy with dapagliflozin and metformin on the state of carbohydrate, lipid and protein metabolism, indicators of liver tests and synthetic liver function in patients with type 2 diabetes, representatives of the Ukrainian population, who have signs of high cardiovascular risk. Materials and Methods: The study included 60 patients with type 2 diabetes, of whom 34 were men and 26 were women. The average age of the patients was (57.52 ± 0.96) years. 39 (65.0%) patients had diabetes of moderate severity, 21 (35.0%) had severe diabetes. 11 patients (18.3%) received combined therapy including insulin. Treatment of patients with type 2 diabetes included adherence to dietary recommendations, namely, nutritional correction and the appointment of tableted oral hypoglycemic agents: dapagliflozin in a daily dose of 10 mg and metformin in a daily dose of 1500 to 2000 mg; 11 patients were additionally prescribed insulin therapy in addition to the oral hypoglycemic drugs. Determination of the level of carbohydrate, lipid, and protein metabolism, indicators of liver tests, and liver synthetic function were performed in all patients. Results: Long-term treatment with dapagliflozin in combination with metformin in patients with type 2 diabetes with a high cardiovascular risk has proven its effectiveness. A significant improvement in carbohydrate, lipid, and protein metabolism indicators, liver test results, and liver synthetic function was established in the treated patients. Conclusions: The expediency and effectiveness of using the combination of the drug dapagliflozin in combination with metformin as a long-term glucose-lowering therapy for patients with type 2 diabetes with comorbid pathology and high cardiovascular risk have been substantiated.
Features of excretion of melatonin in urine in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease with manifestations of fibrosis and its relationship with certain metabolic and immunological indicators
(2018) Zemlianitsyna, Olga; Polozova, Liubov; Karachentsev, Iurii; Sinaiko, Vadym; Kravchun, Nonna
To study the features of secretion of melatonin in the urine in patients with DM type 2 and NAFLD with manifestations of fibrosis and its relationship with some metabolic and immunological parameters, 23 patients with DM type 2 and NAFLD were examined. The degree of fibrosis in patients was diagnosed on the basis of static elastography and the study of indirect fibrosis markers 16 persons (72%) diagnosed with mild fibrosis (F0-F1 on METAVIR), 5 people (18.2%) – with moderate fibrosis (F2-F3 on METAVIR). Only 2 (8.7%) patients did not have any fibrotic disorders, so they were excluded from the further study. All patients underwent determination of melatonin excretion of albumin and in daily urine, as well as the determination of homocysteine in the blood. The level of excretion of melatonin in the urine in patients with DM type 2 and NAFLD did not depend on the degree of fibrosis and on the average was 89.50±16.66 mmol/day, which exceeded the reference values. It has been established that the increase in melatonin level in patients with DM type 2 and NAFLD is associated with the presence of fibrotic changes in the liver and a decrease in the activity of the inflammatory process. In addition, a direct correlation was found between the excretion of melatonin and homocysteine (r=0.43), as well as between melatonin and albumin excretion in the urine (r=0.20). Thus, an increased level of excretion of melatonin in the urine can be not only a marker of liver fibrosis, but also a predictor of cardiovascular disorders in patients with DM type 2 and NAFLD.
Indicators of central cardiohemodynamics in patients with arterial hypertension with postinfarction cardiosclerosis and diabetes mellitus type 2
(2021) Dunaieva, Inna; Vasyliev, Leonid; Kozakov, Aleksandr; Kravchun, Nonna
Central hemodynamic parameters in 40 patients with arterial hypertension, postinfarction cardiosclerosis and type 2 diabetes were evaluated. Based on the study, it is proved that type 2 diabetes mellitus is a predictor of concentric LV myocardial hypertrophy, which can be considered as a reaction of the heart to prolonged increased load and disruption of myocardial microcirculation, contributes to complex structural and functional reorganization of the heart with a tendency to reduce myocardial contractility. Comorbidity of hypertension, postinfarction cardiosclerosis and type 2 diabetes increases the incidence of signs of left ventricular diastolic dysfunction type 1 (type of relaxation disorder), which leads to a worsening of the prognosis of cardiovascular complications.
Influence Of Carbohydrate Metabolism Compensation on The Heart Failure Development in Patients with Arterial Hypertension and Obesity
(2022-06) Біловол, Олександр Миколайович; Князькова, Ірина Іванівна; Дунаєва, Інна Павлівна; Кравчун, Нонна Олександрівна; Bilovol, Olexandr; Knyazkova, Iryna; Dunaieva, Inna; Kravchun, Nonna
Background: Arterial hypertension, especially in combination with diabetes mellitus, which significantly increases the risk of microand macrovascular complications, with hypercholesterinemia, coronary artery disease, congestive heart failure, is the main risk factor for the premature development of atherosclerosis, which generally leads to the development of severe long-term cardiovascular adverse effects. The aim of this study was to determine the state of carbohydrate metabolism compensation and its possible impact on the development of congestive heart failure, its progression in patients with hypertension and obesity. Materials and Methods: A comprehensive examination of 34 patients with arterial hypertension and obesity and type II diabetes mellitus, 32 patients with AH and type II DM, 36 patients with AH and obesity, and 30 patients with AH has been carried out. The Control group consisted of 20 healthy individuals without arterial hypertension and carbohydrate metabolism disorders.
Nutrient correction of cardiovascular risk factors in patients with 2 type diabetes mellitus and non-alcoholic fatty liver disease
(2018) Karachentsev, Iurii; Kravchun, Nonna; Dunaieva, Inna; Zemlianitsyna, Olha; Polozova, Liubov; Dorosh, Olena; Cherniavska, Iryna; Cherniayeva, Anna; Romanova, Iryna; Sinaiko, Vadym; Lavrinenko, Olga
Nutrient correction of cardiovascular risk factors in patients with 2 type diabetes mellitus and non-alcoholic fatty liver disease
(2017) Karachentsev, Iurii; Kravchun, Nonna; Dunaieva, Inna; Zemlianitsyna, Olha; Polozova, Liubov; Dorosh, Olena; Cherniavska, Iryna; Cherniayeva, Anna; Romanova, Iryna; Sinaiko, Vadym; Lavrinenko, Olga
Relationship between NAFLD and Cardiac Complications and Function in T2DM
(2020-01) Lavrynenko, Olga; Zemlianitsyna, Olha; Dunaieva, Inna; Kravchun, Nonna; Sinaiko, Vadim; Defronzo, Ralph A.
Liver fibrosis in T2DM is associated with impaired cardiac function and increased cardiovascular complications. The results demonstrate that hepatic inflammation and fibrosis in T2DM patients with NAFLD is an important risk factor for cardiovascular disease and is associated with cardiac dysfunction.